JP2021118723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021118723A5 JP2021118723A5 JP2021075261A JP2021075261A JP2021118723A5 JP 2021118723 A5 JP2021118723 A5 JP 2021118723A5 JP 2021075261 A JP2021075261 A JP 2021075261A JP 2021075261 A JP2021075261 A JP 2021075261A JP 2021118723 A5 JP2021118723 A5 JP 2021118723A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- immune cell
- vector
- protein
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023086702A JP2023109956A (ja) | 2015-09-09 | 2023-05-26 | 免疫療法のためのマクロファージの遺伝子組換え |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216224P | 2015-09-09 | 2015-09-09 | |
| US62/216,224 | 2015-09-09 | ||
| US201662361348P | 2016-07-12 | 2016-07-12 | |
| US62/361,348 | 2016-07-12 | ||
| JP2018512998A JP6959909B2 (ja) | 2015-09-09 | 2016-09-07 | 免疫療法のためのマクロファージの遺伝子組換え |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512998A Division JP6959909B2 (ja) | 2015-09-09 | 2016-09-07 | 免疫療法のためのマクロファージの遺伝子組換え |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023086702A Division JP2023109956A (ja) | 2015-09-09 | 2023-05-26 | 免疫療法のためのマクロファージの遺伝子組換え |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021118723A JP2021118723A (ja) | 2021-08-12 |
| JP2021118723A5 true JP2021118723A5 (https=) | 2021-12-09 |
| JP7298103B2 JP7298103B2 (ja) | 2023-06-27 |
Family
ID=58240865
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512998A Active JP6959909B2 (ja) | 2015-09-09 | 2016-09-07 | 免疫療法のためのマクロファージの遺伝子組換え |
| JP2021075261A Active JP7298103B2 (ja) | 2015-09-09 | 2021-04-27 | 免疫療法のためのマクロファージの遺伝子組換え |
| JP2023086702A Pending JP2023109956A (ja) | 2015-09-09 | 2023-05-26 | 免疫療法のためのマクロファージの遺伝子組換え |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512998A Active JP6959909B2 (ja) | 2015-09-09 | 2016-09-07 | 免疫療法のためのマクロファージの遺伝子組換え |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023086702A Pending JP2023109956A (ja) | 2015-09-09 | 2023-05-26 | 免疫療法のためのマクロファージの遺伝子組換え |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10525082B2 (https=) |
| EP (1) | EP3347026A4 (https=) |
| JP (3) | JP6959909B2 (https=) |
| CN (1) | CN108243607A (https=) |
| AU (1) | AU2016318773B2 (https=) |
| CA (1) | CA2997912A1 (https=) |
| HK (1) | HK1257460A1 (https=) |
| SG (1) | SG10201913151TA (https=) |
| WO (1) | WO2017044487A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201418965D0 (https=) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CN108243607A (zh) | 2015-09-09 | 2018-07-03 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用于免疫疗法的巨噬细胞的遗传工程 |
| EP3411479A4 (en) | 2016-02-04 | 2019-09-18 | Zhenglun Zhu | TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISEASES |
| US11753653B2 (en) | 2016-03-25 | 2023-09-12 | Periphagen, Inc. | High-transducing HSV vectors |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| WO2018183447A1 (en) * | 2017-03-28 | 2018-10-04 | Zhenglun Zhu | Methods of treating neoplastic diseases |
| EP4317422A3 (en) * | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN118147137A (zh) * | 2017-05-17 | 2024-06-07 | 西雅图儿童医院（Dba西雅图儿童研究所） | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 |
| EP3652318A1 (en) | 2017-07-11 | 2020-05-20 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| BR112020008478A2 (pt) * | 2017-11-01 | 2020-10-20 | Editas Medicine, Inc. | métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia |
| WO2019099993A1 (en) * | 2017-11-17 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for alleviating cytokine release syndrome |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US11267866B2 (en) | 2018-04-04 | 2022-03-08 | Nant Holdings Ip, Llc | Immunoglobulin complex comprising interleukin-15 |
| TWI784324B (zh) * | 2018-04-12 | 2022-11-21 | 美商凱特製藥公司 | 利用腫瘤微環境之特性之嵌合受體t細胞治療 |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| JP7555822B2 (ja) | 2018-04-19 | 2024-09-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | ゲノム編集のための組成物および方法 |
| US12410231B2 (en) | 2018-05-07 | 2025-09-09 | Board Of Regents Of The University Of Texas System | Natural killer cell products and methods |
| US12527821B2 (en) | 2018-05-15 | 2026-01-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tumor cell killers and vaccines |
| US20210254068A1 (en) * | 2018-06-19 | 2021-08-19 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CN108823171A (zh) * | 2018-07-24 | 2018-11-16 | 武汉赛云博生物科技有限公司 | 一种基因工程细胞及体外高效扩增nk细胞的方法 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| GB201818110D0 (en) * | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| EP3883585A4 (en) * | 2018-11-20 | 2022-12-14 | Innovative Cellular Therapeutics Holdings, Ltd. | MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF |
| US20220056479A1 (en) * | 2018-12-17 | 2022-02-24 | Cure Genetics Co., Ltd. | Method For Delivering Gene In Cells |
| EP3917967A4 (en) * | 2019-02-01 | 2023-02-08 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Microenvironment sensors to regulate engineered gene expression |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CN113748124A (zh) * | 2019-02-27 | 2021-12-03 | 阿克蒂姆治疗有限公司 | 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌 |
| JP2022531814A (ja) * | 2019-03-12 | 2022-07-12 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 改変細胞の増幅およびその応用 |
| WO2020198510A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| CN110760480B (zh) * | 2019-07-09 | 2021-07-02 | 杭州师范大学 | 一种抗肿瘤nk细胞及其制备方法 |
| JP7831937B2 (ja) | 2019-09-03 | 2026-03-17 | クリエイト・メディシンズ，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| US20210238258A1 (en) * | 2019-09-11 | 2021-08-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| CA3151223A1 (en) * | 2019-09-17 | 2021-03-25 | Pravin T.P. Kaumaya | Human anti-pd-l1 peptide vaccines and methods of their use |
| WO2021064655A1 (en) * | 2019-10-02 | 2021-04-08 | Massachusetts Institute Of Technology | High-throughput genetic screening |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN111150748A (zh) * | 2019-12-27 | 2020-05-15 | 杭州荣谷生物科技有限公司 | 重组溶瘤病毒在制备治疗消化道癌药物中的用途 |
| CN111087460B (zh) * | 2020-01-14 | 2021-07-30 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种广谱型抗菌肽及其应用 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| IL296511A (en) | 2020-03-20 | 2022-11-01 | Lyell Immunopharma Inc | Novel recombinant cell surface markers |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| GB202007906D0 (en) | 2020-05-27 | 2020-07-08 | Univ Edinburgh | Method of transfecting macrophages |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| CN115867294A (zh) | 2020-06-04 | 2023-03-28 | 凯瑞斯马治疗公司 | 嵌合抗原受体的新型构建体 |
| US20230226181A1 (en) * | 2020-06-22 | 2023-07-20 | Nanjing Legend Biotech Co., Ltd. | GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| TW202241508A (zh) * | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| KR20240055714A (ko) * | 2021-07-09 | 2024-04-29 | 레전드 바이오테크 아일랜드 리미티드 | 돌연변이 il-15 조성물 및 이의 방법 |
| WO2023053828A1 (ja) * | 2021-09-30 | 2023-04-06 | テルモ株式会社 | 化学療法制御装置、化学療法制御システム、化学療法制御装置の制御方法及び化学療法制御プログラム |
| US20250000974A1 (en) * | 2021-10-27 | 2025-01-02 | The Regents Of The University Of California | Combination of human natural killer cells and macrophages for cancer therapy |
| CN114404600B (zh) * | 2022-01-21 | 2023-06-27 | 首都医科大学附属北京同仁医院 | 一种用于治疗肿瘤的药物组合及其应用 |
| CN114657143B (zh) * | 2022-03-11 | 2022-10-25 | 西安电子科技大学 | 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用 |
| IL316314A (en) * | 2022-04-18 | 2024-12-01 | Candel Therapeutics Inc | Compositions and methods for viral vectors |
| US20250312486A1 (en) * | 2022-04-18 | 2025-10-09 | City Of Hope | Compositions for restoring mecp2 gene function and methods of use thereof |
| WO2024215990A2 (en) * | 2023-04-13 | 2024-10-17 | William Marsh Rice University | Regulated cells expressing cytokines |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
| WO2026062037A1 (en) | 2024-09-18 | 2026-03-26 | Myllia Biotechnology Gmbh | Gene perturbation in human monocyte-derived macrophages |
| WO2026069312A1 (en) | 2024-09-24 | 2026-04-02 | Yeda Research And Development Co. Ltd. | Immune cells expressing an inducible therapeutic agent and uses thereof |
| CN119020422A (zh) * | 2024-10-28 | 2024-11-26 | 昆明医科大学 | 一种稳转萤火虫萤光素酶靶细胞株的构建方法及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2286819A1 (en) | 1997-04-17 | 1998-10-22 | Flossie Wong-Staal | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US7432351B1 (en) * | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| KR101441843B1 (ko) | 2005-10-18 | 2014-09-17 | 내셔날 쥬이쉬 헬스 | 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법 |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| US9023648B2 (en) * | 2009-12-30 | 2015-05-05 | University Of Massachusetts | Method of transducing non-dividing myeloid cells utilizing chimeric murine leukemia viruses containing Vpx |
| BR112012024565B1 (pt) * | 2010-03-26 | 2022-02-08 | Trustees Of Dartmouth College | Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição |
| CN110200997A (zh) * | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US8323662B1 (en) * | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2906684B8 (en) * | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| WO2014164544A1 (en) * | 2013-03-09 | 2014-10-09 | Baylor College Of Medicine | Vascular-targeted t-cell therapy |
| US9587032B2 (en) * | 2013-06-12 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | IgE antibodies for the inhibition of tumor metastasis |
| ES2792849T3 (es) | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| RU2766690C2 (ru) | 2015-07-28 | 2022-03-15 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения |
| US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| CN108243607A (zh) | 2015-09-09 | 2018-07-03 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用于免疫疗法的巨噬细胞的遗传工程 |
-
2016
- 2016-09-07 CN CN201680065510.4A patent/CN108243607A/zh active Pending
- 2016-09-07 CA CA2997912A patent/CA2997912A1/en active Pending
- 2016-09-07 JP JP2018512998A patent/JP6959909B2/ja active Active
- 2016-09-07 AU AU2016318773A patent/AU2016318773B2/en active Active
- 2016-09-07 SG SG10201913151TA patent/SG10201913151TA/en unknown
- 2016-09-07 EP EP16844978.3A patent/EP3347026A4/en active Pending
- 2016-09-07 WO PCT/US2016/050552 patent/WO2017044487A1/en not_active Ceased
- 2016-09-07 HK HK18116695.4A patent/HK1257460A1/zh unknown
- 2016-09-07 US US15/258,887 patent/US10525082B2/en active Active
-
2019
- 2019-11-25 US US16/694,024 patent/US11826384B2/en active Active
-
2021
- 2021-04-27 JP JP2021075261A patent/JP7298103B2/ja active Active
-
2023
- 2023-05-26 JP JP2023086702A patent/JP2023109956A/ja active Pending
- 2023-10-17 US US18/488,400 patent/US20240091256A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021118723A5 (https=) | ||
| JP2018528774A5 (https=) | ||
| Yang et al. | Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity | |
| TWI850282B (zh) | 用於治療癌症之質體建構體和使用方法 | |
| Sharma et al. | SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10 | |
| Homey et al. | Chemokines: agents for the immunotherapy of cancer? | |
| Ellyard et al. | Th2‐mediated anti‐tumour immunity: friend or foe? | |
| EP1200479B1 (en) | Multiple cytokine-antibody complexes | |
| JP2018514199A5 (https=) | ||
| JP2021519089A5 (https=) | ||
| Hashimoto et al. | Type I IFN gene delivery suppresses regulatory T cells within tumors | |
| US20050053579A1 (en) | Novel synthetic chimeric fusion transgene with immuno-therapeutic uses | |
| JP7423607B2 (ja) | インターロイキン ２突然変異タンパク質およびｉ型インターフェロンで構成される融合タンパク質 | |
| Ruehlmann et al. | MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma | |
| US20100297076A1 (en) | Targeted interferon demonstrates potent apoptotic and anti-tumor activities | |
| JP2022511135A (ja) | アルブミン結合ドメイン融合タンパク質 | |
| JPWO2019191519A5 (https=) | ||
| JP2026000910A (ja) | 免疫回避腫瘍の処置 | |
| B Maschio-Signorini et al. | Melatonin regulates angiogenic and inflammatory proteins in MDA-MB-231 cell line and in co-culture with cancer-associated fibroblasts | |
| US20250367236A1 (en) | Engineered immune cells | |
| JP6952603B2 (ja) | クラミジア活性化ｂ細胞プラットフォーム及びその方法 | |
| JP2021516957A5 (https=) | ||
| KR100788930B1 (ko) | 항암 조성물 | |
| JPWO2019148109A5 (https=) | ||
| Rodríguez et al. | Immunotherapy of murine hepatocellular carcinoma by α-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression |